Literature DB >> 3293838

The comparative tissues distribution of platinum and 14C in mice receiving 14C-labelled carboplatin.

S E Dible1, Z H Siddik, K R Harrap.   

Abstract

Since the reactivity of carboplatin depends on the rate of removal of the 1,1-cyclobutanedicarboxylate ligand, the time course of this dissociation has been determined in various tissue and body fluids using 14C-labelled carboplatin (cis-diammine[1,1-cyclobutane-1-14C-dicarboxylate]platinum II). Mice received 14C-carboplatin (80 mg/kg; 1.1 mCi/kg, i.v.), and tissue was removed at times ranging from 5 min to 5 days posttreatment. Following solubilization, tissue aliquots were analyzed for platinum and 14C contents. Carboplatin remained intact for up to 2 h posttreatment, since the ratio of 14C: Pt in tissues (nmol/g) was unity. Thereafter, the 14C ligand was released from the molecule and preferentially removed from tissues, indicated by decreasing 14C: Pt ratios. The elimination half-lives for Pt varied between tissues (40-156 h). In contrast, the corresponding half-lives for the 14C species were similar in most types of tissue (18-35 h), although those in the liver and spleen were exceptional (210 and 90 h, respectively). At 5 days a maximum of 4%-24% of the total Pt in tissue might exist as intact drug. Thus, the metabolic handling of carboplatin varies according to the tissue, since the elimination of the 14C cyclobutane dicarboxylate species from most tissue was similar and Pt elimination was slower and tissue-dependent.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3293838     DOI: 10.1007/bf00254173

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  15 in total

1.  Distribution of cis-platin in blood.

Authors:  R C Manaka; W Wolf
Journal:  Chem Biol Interact       Date:  1978-09       Impact factor: 5.192

2.  Ovarian trials at the Royal Marsden.

Authors:  E Wiltshaw
Journal:  Cancer Treat Rev       Date:  1985-09       Impact factor: 12.111

3.  Carboplatin (JM8) as a single agent and in combination in the treatment of small cell lung cancer.

Authors:  I E Smith; B D Evans
Journal:  Cancer Treat Rev       Date:  1985-09       Impact factor: 12.111

4.  Platinum levels in human erythrocytes following intravenous administration of cisplatin: importance of erythrocytes as a distribution site for platinum species.

Authors:  D F Long; T F Patton; A J Repta
Journal:  Biopharm Drug Dispos       Date:  1981 Apr-Jun       Impact factor: 1.627

5.  Early clinical studies with cis-diammine-1,1-cyclobutane dicarboxylate platinum II.

Authors:  A H Calvert; S J Harland; D R Newell; Z H Siddik; A C Jones; T J McElwain; S Raju; E Wiltshaw; I E Smith; J M Baker; M J Peckham; K R Harrap
Journal:  Cancer Chemother Pharmacol       Date:  1982       Impact factor: 3.333

6.  A comparative study of the distribution in the male rat of platinum-labelled cis-dichlorodiammine platinum (II), cis-trans-dichlorodihydroxy-bis-(isopropylamine) platinum (I), and cis-dichloro-bis-cyclopropylamine platinum (II).

Authors:  R Harrison; C A McAuliffe; A Zaki; J Baer; H Sharma; A Smith; H Jackson; B W Fox
Journal:  Cancer Chemother Pharmacol       Date:  1983       Impact factor: 3.333

7.  Pharmacokinetic study of cis-dichlorodiammineplatinum(II) (DDP) in the beagle dog: thermodynamic and kinetic behavior of DDP in a biologic millieu.

Authors:  A F LeRoy; R J Lutz; R L Dedrick; C L Litterst; A M Guarino
Journal:  Cancer Treat Rep       Date:  1979-01

8.  Nephrotoxic potential of cis-diamminedichloroplatinum and four analogs in male Fischer 344 rats.

Authors:  B S Levine; M C Henry; C D Port; W R Richter; M A Urbanek
Journal:  J Natl Cancer Inst       Date:  1981-07       Impact factor: 13.506

9.  In vivo distribution studies of radioactively labelled platinum complexes; cis-dichlorodiammine platinum(II), cis-trans-dichlorodihydroxy-bis-(isopropylamine) platinum(IV), cis-dichloro-bis-cyclopropylamine platinum(II), and cis-diammine 1,1-cyclobutanedicarboxylate platinum(II) in patients with malignant disease, using a gamma camera.

Authors:  S E Owens; N Thatcher; H Sharma; N Adam; R Harrison; A Smith; A Zaki; J C Baer; C A McAuliffe; D Crowther
Journal:  Cancer Chemother Pharmacol       Date:  1985       Impact factor: 3.333

10.  Results of NCI-sponsored phase I trials with carboplatin.

Authors:  B J Foster; K Clagett-Carr; B Leyland-Jones; D Hoth
Journal:  Cancer Treat Rev       Date:  1985-09       Impact factor: 12.111

View more
  2 in total

Review 1.  Clinical pharmacokinetics of carboplatin.

Authors:  W J van der Vijgh
Journal:  Clin Pharmacokinet       Date:  1991-10       Impact factor: 6.447

2.  Synergistic antitumor effects of carboplatin and interferons on hepatic metastases of colon carcinoma 26 and M5076 reticulum cell sarcoma.

Authors:  M Iigo; I Shimizu; K Sagawa
Journal:  Jpn J Cancer Res       Date:  1993-07
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.